Skip to main content

Novartis Recalls 100 mg Sandimmune and Neoral Prescription Drug Blister Packages Due to Failure to Meet Child-Resistant Packaging Requirement; Risk of Poisoning

  • Recalled Neoral® 100 mg soft gelatin capsules
  • Recalled Sandimmune® 100 mg soft gelatin capsules
Name of Product:
Sandimmune® (cyclosporine capsules, USP) 100 mg soft gelatin capsules and Neoral® (cyclosporine capsules, USP) MODIFIED 100 mg soft gelatin capsules prescription drug blister packages

The prescription drug packaging is not child resistant as required by the Poison Prevention Packaging Act (PPPA), posing a risk of poisoning if the contents are swallowed by young children.

New Instructions
Recall Date:
March 18, 2020
About 73,000
Consumer Contact

Novartis toll-free at 866-629-6182 from 8 a.m. to 8 p.m. ET daily, email at or online at and in the top navigation of the page go to the News tab and click on Statements, or visit for more information.

Recall Details


This recall involves blister packages of prescription medications Sandimmune® (cyclosporine capsules, USP) 100 mg soft gelatin capsules and Neoral® (cyclosporine capsules, USP) MODIFIED 100 mg soft gelatin capsules from Novartis. Packages of Sandimmune 100 mg contain three blister cards with ten soft gelatin capsules per card and packages of Neoral 100 mg contain five blister cards with six soft gelatin capsules per card. The recalled blister packages have “Novartis,” the name of the medication, dosage, NDC, lot number and expiration date on the outer package and on the blister cards. Only 100 mg doses of these medications with the following NDC and lot numbers and expiration dates are included in this recall:


Recalled Prescription Drugs

NDC Numbers

Lot Numbers

Expiration Date

Sandimmune® (cyclosporine capsules, USP) 100 mg soft gelatin capsules








02/2021 01/2022


Neoral® (cyclosporine capsules, USP) MODIFIED 100 mg soft gelatin capsules









Consumers should immediately secure the product out of the sight and reach of children and contact the firm to request a free child-resistant pouch in which to store the blister package medications. Consumers can continue to use the medication as directed. The child-resistant pouches should be used to store these medications until new child-resistant blister packaging is available.


None reported.

Sold At:
Clinics and pharmacies nationwide as a prescribed medicine from March 2018 through March 2020, at prices varying based on quantities prescribed, health insurance terms, and other factors.
Novartis Pharmaceuticals Corporation, of East Hanover, N.J.
Manufactured In:
United States
Recall number:

Note: Individual Commissioners may have statements related to this topic. Please visit to search for statements related to this or other topics.

If you are experiencing issues with a recall remedy or believe a company is being non-responsive to your remedy request, please use this form and explain the situation to CPSC.
About the U.S. CPSC

The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risk of injury or death associated with the use of thousands of types of consumer products. Deaths, injuries, and property damage from consumer product-related incidents cost the nation more than $1 trillion annually. CPSC's work to ensure the safety of consumer products has contributed to a decline in the rate of injuries associated with consumer products over the past 50 years.

Federal law prohibits any person from selling products subject to a Commission ordered recall or a voluntary recall undertaken in consultation with the CPSC.

For lifesaving information:
Choose Your Recall Emails Get Notified About Each Recall via Email.
Report an unsafe product